Jerome Barakos

ORCID: 0000-0001-9117-2788
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Alzheimer's disease research and treatments
  • Intracerebral and Subarachnoid Hemorrhage Research
  • Dementia and Cognitive Impairment Research
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Advanced MRI Techniques and Applications
  • Epilepsy research and treatment
  • Advanced Neuroimaging Techniques and Applications
  • Functional Brain Connectivity Studies
  • Neuroscience and Neuropharmacology Research
  • Medical Imaging Techniques and Applications
  • Neurological disorders and treatments
  • MRI in cancer diagnosis
  • Marine Toxins and Detection Methods
  • Glioma Diagnosis and Treatment
  • Meningioma and schwannoma management
  • Statistical Methods in Clinical Trials
  • Pediatric Urology and Nephrology Studies
  • Nicotinic Acetylcholine Receptors Study
  • Parkinson's Disease Mechanisms and Treatments
  • Radiomics and Machine Learning in Medical Imaging
  • Cerebrospinal fluid and hydrocephalus
  • Renal cell carcinoma treatment
  • Head and Neck Surgical Oncology
  • Gallbladder and Bile Duct Disorders
  • Health Systems, Economic Evaluations, Quality of Life

Imaging Center
2024

Mayo Clinic
2024

University College London
2009-2024

Cornell University
2024

California Pacific Medical Center
2012-2023

BioClinica (United States)
2016-2022

Sutter Health
2022

University of California, San Francisco
1986-2016

Biogen (United Kingdom)
2016

Biogen (United States)
2016

The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment aducanumab, an amyloid-β (Aβ)-targeting monoclonal antibody, in patients mild cognitive impairment due Alzheimer disease or dementia. To describe the radiographic characteristics ARIA occurred ENGAGE. Secondary analysis from trials, which were 2 double-blind, placebo-controlled, parallel-group, compared...

10.1001/jamaneurol.2021.4161 article EN cc-by-nc-nd JAMA Neurology 2021-11-22

Monoclonal antibodies are emerging disease-modifying therapies for Alzheimer disease that require brain MR imaging eligibility assessment as well monitoring amyloid-related abnormalities. Amyloid-related abnormalities result from treatment-related loss of vascular integrity and may occur in 2 forms. with edema or effusion transient, treatment-induced sulcal effusion, identified on T2-FLAIR. hemorrhage microhemorrhages superficial siderosis T2* gradient recalled-echo. As monoclonal become...

10.3174/ajnr.a7586 article EN cc-by American Journal of Neuroradiology 2022-08-11

Harmful algal blooms are increasing worldwide, including those of Pseudo-nitzschia spp. producing domoic acid off the California coast. This neurotoxin was first shown to cause mortality marine mammals in 1998. A decade monitoring sea lion (Zalophus californianus) health since then has indicated that changes symptomatology and epidemiology toxicosis this species associated with increase toxigenic blooms. Two separate clinical syndromes now exist: acute as been previously documented, a second...

10.1098/rspb.2007.1221 article EN Proceedings of the Royal Society B Biological Sciences 2007-11-15

Amyloid positron emission tomography (PET) imaging is being investigated as a screening tool to identify amyloid-positive patients an enrichment strategy for Alzheimer disease (AD) clinical trial enrollment. In multicenter, phase 1b trial, meeting criteria prodromal or mild AD underwent florbetapir PET scanning at screening. PET, magnetic resonance imaging, and coregistered PET/magnetic scans were reviewed by 2 independent readers binary visual readings tabulated. Semiquantitative values of...

10.1097/wad.0000000000000144 article EN Alzheimer Disease & Associated Disorders 2016-01-01

The high signal intensity of fat on T1-weighted magnetic resonance images has limited the utility gadopentetate dimeglumine in imaging extracranial head and neck. Enhancing lesions may be obscured either by proximity to or chemical misregistration artifact. authors evaluated role a gadolinium-enhanced suppression technique detection neck abnormalities 29 patients. These studies were directly compared with conventional pre- postcontrast T1- T2-weighted SE sequences. In detecting defining...

10.1148/radiology.179.1.2006277 article EN Radiology 1991-04-01

To evaluate the frequency of retroperitoneal hemorrhage related to renal biopsy, we prospectively assessed 182 patients (200 biopsies) using state-of-the-art CT and ultrasound. Our study revealed definite evidence after 90.9% biopsies. In a blinded analysis images obtained in biopsied unbiopsied control overall accuracy was 93.8 versus 76.4% for data suggest that detectable is virtually always seen biopsy its much higher than noted earlier studies.

10.1097/00004728-198711000-00021 article EN Journal of Computer Assisted Tomography 1987-11-01

The magnetic resonance (MR) imaging characteristics of lateral tibial rim (Segond) fractures and their associated injuries were reviewed in 12 patients with radiographic evidence this fracture. Bone marrow adjacent to the fracture emitted a focally abnormal MR signal, which indicated an injury capsular junction. Segond fragment, however, was seen on images only four patients. Associated ligamentous meniscal identified arthroscopy involved anterior (n = 11) medial 7) cruciate ligaments 4) 1)...

10.1148/radiology.180.3.1871286 article EN Radiology 1991-09-01

Computed tomography (CT) is often the first imaging modality used in diagnosis of patients with suspected abdominal disease. While it known that early generation CT scanners detect gallstones, detection rate newer equipment not widely known. Abdominal scans 226 who had undergone ultrasonographic (US) studies gallbladder were reviewed a blinded study to determine accuracy state-of-the-art scanning cholelithiasis. Of 110 US or surgical evidence cholelithiasis, gallstones demonstrated on images...

10.1148/radiology.162.2.3797654 article EN Radiology 1987-02-01

High-resolution magnetic resonance imaging (MRI) at 4 Tesla depicts details of the internal structure hippocampus not visible 1.5 Tesla, and so allows for in vivo parcellation different hippocampal subfields. The aim this study was to test if distinct subfield atrophy patterns can be detected temporal lobe epilepsy (TLE) with mesial sclerosis (TLE-MTS) without (TLE-no) sclerosis.High-resolution T(2)-weighted images were acquired 34 controls: 15 TLE-MTS 18 TLE-no. Entorhinal cortex (ERC),...

10.1111/j.1528-1167.2009.02010.x article EN Epilepsia 2009-03-12

Cerebral vasogenic edema (VE) has been reported to occur during antiamyloid immunotherapy. VE may be associated with central nervous system pathology blood-brain barrier disruptions; however, less is known about the prevalence of naturally occurring in patients Alzheimer's disease (AD).Fluid-attenuated inversion recovery imaging sequences were obtained from four ongoing multicenter, randomized, double-blind, placebo-controlled, phase 3 trials mild-to-moderate AD. The first set baseline scans...

10.1016/j.jalz.2011.05.2353 article EN Alzheimer s & Dementia 2011-07-01

Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD).Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks 80 1457 patients entered an open-label extension. Magnetic resonance imaging scans monitored amyloid-related abnormalities-edema/effusion (ARIA-E) abnormalities-hemorrhage/hemosiderin deposition.Sixteen (solanezumab, n 11;...

10.1016/j.dadm.2016.02.004 article EN cc-by-nc-nd Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2016-01-01

Amyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild moderate dementia Alzheimer's disease (AD) and have been reported increased incidence clinical trials of amyloid-lowering therapies under development for AD.Our objective was explore the relationship between incidences ARIA-H during treatment placebo different doses bapineuzumab, a humanised monoclonal antibody directed against amyloid β.Two neuroradiologists independently reviewed 2572...

10.1136/jnnp-2014-309493 article EN cc-by-nc Journal of Neurology Neurosurgery & Psychiatry 2015-02-10

Abstract Background The positron emission tomography (PET) radiotracer [ 18 F]MK‐6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), sensitivity to medial temporal and neocortical NFTs, low within‐brain background. Objectives were develop validate a reproducible, clinically relevant visual read method supporting use identify stage AD subjects versus non‐AD controls. Methods Five expert readers used their own methods assess 30 scans...

10.1002/trc2.12372 article EN cc-by-nc-nd Alzheimer s & Dementia Translational Research & Clinical Interventions 2023-01-01

Summary Purpose: The thalamus plays an important role in seizure propagation temporal lobe epilepsy (TLE). This study investigated how structural abnormalities the focus, ipsilateral and extrafocal cortical structures relate to each other TLE with mesiotemporal sclerosis (TLE‐MTS) without hippocampal (TLE‐no). Methods: T 1 high‐resolution 2 images were acquired on a 4T magnet 29 controls, 15 TLE‐MTS cases, 14 TLE‐no. Thalamus volumes obtained by warping labeled atlas onto subject’s brain....

10.1111/j.1528-1167.2009.02413.x article EN Epilepsia 2009-12-01

We previously demonstrated relatively intact cognitive function (with the exception of suggestive evidence for persistent deficits in spatial information processing) middle-aged long-term abstinent alcoholics (LTAA, 6 months or more) compared to age and gender comparable nonalcoholic controls (NAC) (Fein et al., 2006).In current study, we examine cortical gray matter volumes same samples determine whether LTAA are consistent with results--i.e., exhibiting NAC most brain regions, except...

10.1111/j.1530-0277.2009.01019.x article EN Alcoholism Clinical and Experimental Research 2009-07-23
Coming Soon ...